Please ensure Javascript is enabled for purposes of website accessibility

Why Aphria, OrganiGram Holdings, and Aurora Cannabis Rose Today

By Howard Smith - Apr 19, 2021 at 2:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Consolidation is likely good for the burgeoning industry, but the marijuana sector remains speculative and immature.

What happened

Shares of some Canadian cannabis companies jumped Monday morning, before paring those gains. Shares of Aphria (APHA), OrganiGram Holdings (OGI -3.96%), and Aurora Cannabis (ACB -8.05%) all rose between 6% and 8% early in today's session. Those gains faded some, and as of 2 p.m. EDT, Aphria traded up about 1%, Organigram was up 3.2%, and Aurora was up 3.4%.

So what

The biggest recent news among these Canadian growers was the overwhelming shareholder support the proposed merger between Aphria and Tilray (TLRY) received. Approval of the previously announced combination required a two-thirds majority by voting Aphria shareholders. Late last week, the company revealed that more than 99% of voters approved the plan. Other news in the marijuana sector from last week was OrganiGram Holdings releasing its fiscal 2021 second-quarter financial results.

marijuana bud in front of Canadian flag

Image source: Getty Images.

Now what

The most recent quarterly financial results have been a bit of a mixed bag in the cannabis sector. In its report last week, Aphria said it experienced its eighth straight quarter of positive adjusted EBITDA. But much of the focus was on declining revenue from the previous sequential quarter. Net revenue dropped 4.3% quarter over quarter, and net cannabis revenue dropped nearly 24% in the same comparison. With a post-pandemic recovery presumably under way, that's not a trend investors wanted to see. 

OrganiGram similarly reported a sharp drop in revenue compared to its previous-year period. Management noted lower average selling prices to help explain the 37% drop in year-over-year net revenue. Aurora, which is in the midst of attempting a business turnaround, had better relative results compared to its previous-year period, aided from strength in international medical marijuana sales and product launches in vapes, edibles, and concentrates.

Future success from the Canadian companies is going to depend somewhat on international business. If the U.S. market opens up with federal legalization, it will be a boon for many Canadian companies. In the meantime, the newly combined Aphria and Tilray business is expanding overseas, and preparing for an open U.S. market. Tilray has been expanding into Europe, having made several recent announcements about new business in the U.K., Spain, and Portugal. Aphria acquired Georgia-based craft brewer SweetWater Brewing late last year in part to add distribution infrastructure in the U.S. 

Aphria CEO Irwin Simon told CNBC in a February interview he hopes to see fully legal cannabis in the U.S. within two to three years. Simon will also lead the newly combined company that will use the Tilray name. The CEO said he thinks legalization is likely to happen sooner in Germany, Portugal, and other countries, reinforcing the moves Tilray has been making in the region.

Today's volatility in the stocks is something investors will have to remain accustomed to as they speculate over political outcomes and the future direction of the fledgling industry.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aphria Stock Quote
Aurora Cannabis Stock Quote
Aurora Cannabis
$1.37 (-8.05%) $0.12
OrganiGram Holdings Stock Quote
OrganiGram Holdings
$0.97 (-3.96%) $0.04
Tilray Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.